Naturland Holding Zrt (BUD:NATURLAND) Cash Conversion Cycle: 158.48 (As of Jun. 2025)


BUD:NATURLAND Naturland Holding Zrt BUD:NATURLAND
61 GF Score
Price Ft2,820.00
GF Value Ft2,879.22
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Naturland Holding Zrt Cash Conversion Cycle?

Naturland Holding Zrt BUD:NATURLAND 61 Cash Conversion Cycle is 158.48 as of Jun. 2025. GuruFocus rates BUD:NATURLAND with a GF Score™ of 61/100 and a GF Value™ of Ft2,879.22 (Fairly Valued). The stock has 6 warning signs investors should review.

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Naturland Holding Zrt's Days Sales Outstanding for the six months ended in Jun. 2025 was 30.65.
Naturland Holding Zrt's Days Inventory for the six months ended in Jun. 2025 was 160.59.
Naturland Holding Zrt's Days Payable for the six months ended in Jun. 2025 was 32.76.
Therefore, Naturland Holding Zrt's Cash Conversion Cycle (CCC) for the six months ended in Jun. 2025 was 158.48.


Naturland Holding Zrt  (BUD:NATURLAND) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Naturland Holding Zrt Cash Conversion Cycle Related Terms


Naturland Holding Zrt Cash Conversion Cycle Historical Data

* Premium members only.

The historical data trend for Naturland Holding Zrt's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Naturland Holding Zrt Cash Conversion Cycle Chart

Naturland Holding Zrt Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Cash Conversion Cycle
1,455.03 69.99 145.99 152.13 152.79

Naturland Holding Zrt Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only 155.41 137.72 146.28 148.01 158.48

BUD:NATURLAND vs ZTS, UTHR, VTRS: Cash Conversion Cycle Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Naturland Holding Zrt's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Naturland Holding Zrt Cash Conversion Cycle vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Naturland Holding Zrt's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Naturland Holding Zrt's Cash Conversion Cycle falls into.


BUD:NATURLAND
61GF Score
Naturland Holding Zrt BUD:NATURLAND
Cash Conversion Cycle is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Naturland Holding Zrt Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Naturland Holding Zrt's Cash Conversion Cycle for the fiscal year that ended in Dec. 2024 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=34.99+150.98-33.18
=152.79

Naturland Holding Zrt's Cash Conversion Cycle for the quarter that ended in Jun. 2025 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=30.65+160.59-32.76
=158.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Conversion Cycle →
What does a Cash Conversion Cycle of 158.48 mean?
Naturland Holding Zrt (BUD:NATURLAND) has a Cash Conversion Cycle of 158.48 as of Jun. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Naturland Holding Zrt and its competitors.
Is Naturland Holding Zrt's Cash Conversion Cycle too high?
Naturland Holding Zrt's current Cash Conversion Cycle is 158.48. The Drug Manufacturers industry median Cash Conversion Cycle is 145.72. Naturland Holding Zrt's value of 158.48 is 8.8% above this industry median. Overall, Naturland Holding Zrt has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Naturland Holding Zrt's Cash Conversion Cycle compare to ZTS and UTHR?
Naturland Holding Zrt's Cash Conversion Cycle of 158.48 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.72. Naturland Holding Zrt's value of 158.48 is 8.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.72, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Naturland Holding Zrt's current Cash Conversion Cycle of 158.48 is 8.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Naturland Holding Zrt and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Naturland Holding Zrt's current Cash Conversion Cycle is 158.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naturland Holding Zrt stock overvalued right now?
Based on GuruFocus' analysis, Naturland Holding Zrt (BUD:NATURLAND) is currently considered Fairly Valued. The stock's GF Value™ is Ft2,879.22, compared to a current price of Ft2,820.00 — trading 2.1% below its estimated fair value. The current Cash Conversion Cycle is 158.48 and 8.8% above the Drug Manufacturers industry median of 145.72. Naturland Holding Zrt's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Naturland Holding Zrt (BUD:NATURLAND), the current Cash Conversion Cycle is 158.48 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Naturland Holding Zrt (BUD:NATURLAND) Overvalued in 2026?

Based on GuruFocus' analysis, Naturland Holding Zrt stock appears to be undervalued. The current stock price of Ft2,820.00 is trading 2.1% below its estimated GF Value™ of Ft2,879.22. GuruFocus considers Naturland Holding Zrt to be Fairly Valued.

Key valuation signals for BUD:NATURLAND:

  • Cash Conversion Cycle: 158.48
  • GF Value™: Ft2,879.22 vs. price of Ft2,820.00 (2.1% below fair value)
  • GF Score™: 61/100 with 6 warning signs
  • Industry Position: 8.8% above the Drug Manufacturers median

No single metric tells the full story. See the BUD:NATURLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Naturland Holding Zrt Business Description

Address Csillagvirag utca 8, Budapest, HUN, 1106
Naturland Holding Zrt thro9ugh its subsidiaries engage in the production of pharmaceutical products. It engages in the development, production, and wholesale of dietary supplements and cosmetics, herbal medicine, teas, and essential oils. The firm offers tablets, suppositories, ointments, and ophthalmic base solutions.
61GF Score

Get the complete analysis for BUD:NATURLAND

Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Ft2,820.00
Price
Ft2,879.22
GF Value